A center of the Freeman Spogli Institute for International Studies
FSI’s researchers assess health and medicine through the lenses of economics, nutrition and politics. They’re studying and influencing public health policies of local and national governments and the roles that corporations and nongovernmental organizations play in providing health care around the world. Scholars look at how governance affects citizens’ health, how children’s health care access affects the aging process and how to improve children’s health in Guatemala and rural China. They want to know what it will take for people to cook more safely and breathe more easily in developing countries.
FSI professors investigate how lifestyles affect health. What good does gardening do for older Americans? What are the benefits of eating organic food or growing genetically modified rice in China? They study cost-effectiveness by examining programs like those aimed at preventing the spread of tuberculosis in Russian prisons. Policies that impact obesity and undernutrition are examined; as are the public health implications of limiting salt in processed foods and the role of smoking among men who work in Chinese factories. FSI health research looks at sweeping domestic policies like the Affordable Care Act and the role of foreign aid in affecting the price of HIV drugs in Africa.
Stanford Center at Peking University
The Lee Jung Sen Building
Langrun Yuan
Peking University
No.5 Yiheyuan Road
Haidian District
Beijing, P.R.China 100871
After a successful launch of the first “Essential Interpersonal Dynamics” (EID) China program in July 2018, we are pleased to announce that the 3rd session will take place in December 27-30, 2018, at the Stanford Center at Peking University. The program aims to help increase our ability to forge strong relationships with others, to improve emotional intelligence and leadership through better communications with self and others. The program is adapted from Interpersonal Dynamics, one of most acclaimed and long-running programs at the Stanford Graduate School of Business, known to many as “Touchy Feely”.
The program is being launched following a 2-year pilot overseen by Interpersonal Dynamics faculty member Leslie Chin in which the program design was adapted to Chinese culture and context. Participants will be awarded a certificate issued jointly by Dr. David Bradford, Stanford Graduate School of Business Eugene O’Kelly II Senior Lecturer Emeritus in Leadership and Co-founder of the Interpersonal Dynamics Program, and Leslie Chin, Interpersonal Dynamics faculty member and lecturer in Management.
Program dates: December 27 – 30, 2018
Venue: Stanford Center at Peking University, Beijing
Language: English
Program fee: RMB 18,600
Deadline for registration: November 30, 2018
______________________________________________
Schedule:
Dec 27 17:00 – 22:00 (dinner included, from 17:00 – 17:30)
Dec 28 9:00 – 21:00 (lunch & dinner included)
Dec 29 9:00 – 21:00 (lunch & dinner included)
Dec 30. 9:00 – 16:00 (lunch included)
______________________________________________
Given the small group size and interactive nature of the program, successful applicants must commit to staying throughout the program. Interviews are required for admission. For more information, please contact lapli@stanford.edu.
To register, please fill in the form by November 30th:
http://web.stanford.edu/~lapli/EIDP2018Dec.fb
Stanford Center at Peking University
The Lee Jung Sen Building
Langrun Yuan
Peking University
No.5 Yiheyuan Road
Haidian District
Beijing, P.R.China 100871
Organizers: Stanford Prevention Research Center and Peking University Institute of Child and Adolescent Health
China’s extraordinary economic growth has fostered numerous social changes that threaten to offset the benefits of economic prosperity. Most prominent is rapid urbanization with substantial rural to urban migration. Resulting changes in health behaviors include increases in smoking, alcohol intake, overweight/obesity, pollutant exposure, and sedentary lifestyles. These changes exert distinct pressures on different population segments. Particularly impacted are adolescents and young adults. Unfavorable changes in their health behaviors presage magnified downstream increases in chronic diseases. Numerous problems are increasing in this age group, including substance abuse, depression, risky behavior, weight gain, visual impairment, infertility, and self-harm. China is modifying some economic strategies and shifting towards primary health care as well as adopting policies to directly improve the health of adolescents and young adults.
This all-day symposium focuses on the current health issues in adolescents and young adults and explores an integrated approach to tackle these problems.
AGENDA
9:10am Introduction by Randall Stafford, Stanford Prevention Research Center
9:30am Presentation on "A Chinese perspective on global health – examples from the United Nations" by Gang SUN, United Nations Programme on HIV and AIDS Headquarters
10:15am Break
10:30 Presentation on "Media-based Interventions to Increase Physical Activity in Chinese Youth" by Patrick LAU, Department of Physical Education, Hong Kong Baptist University
11:15am Student Group 1: Improving How Students Eat
11:35am Student Group 2: University Student’s Mental Health
11:55am Student Group 3: Breakfast and Adolescent Health
12:20pm Lunch
1:30pm Presentation on "Healthcare Entrepreneurship for the Youth Population" by Xing-Chuan LAN, Dekai Phamacy
2:15pm Presentation on "Big Data in Health and Medicine: Implications for Adolescents" by Yi NING, Meinian Health Company, Peking University
3:00pm Break
3:10pm Panel Discussion
4:00pm Close
TO REGISTER, PLEASE FILL IN THE FORM: http://web.stanford.edu/~lapli/adolescenthealth.fb
Stanford Center at Peking University
The Lee Jung Sen Building
Langrun Yuan
Peking University
No.5 Yiheyuan Road
Haidian District
Beijing, P.R.China 100871
Over the last decade, significant strides have been made in medical research, which leads to great improvement in human health. During this period, Chinese government has made important progress in promoting and managing medical innovations. Chinese State Drug Administration (SDA, former FDA) is now a formal agency member of the international council for harmonisation of technical requirements for pharmaceuticals for human use (ICH). With further integration of China into the global pharmaceutical research and development, how government regulatory agencies, the related law and regulations can promote industry innovation, while enhance their accountability and responsibility remains an important question. This forum is organized to address this need.
Program: This forum provides a platform for high-level discussions on this topic by Chinese and US scholars from academia, experts from the Chinese Food and Drug Administrations, and R&D experts from biomedical industries. On June 8-9, 2018, the forum will host keynote speech sessions, invited talks, and panel discussion sessions. With collaborations from Chinese evidence based medicine association, we will discuss methods and policy related to monitoring drug safety, novel clinical trial design, and applications of modern statistical, AI and machine learning methods in drug development. On June 10, 2018, a half-day short course will be offered on “Statistical Methods for Medical Product Safety Evaluation.”
Goals: Through this brainstorming and exchange, we want to identify research priorities and collaborative mechanisms for international scholars from academia, regulatory agencies and industry working together to promote biomedical innovations in an efficient and orderly manner.
Format: Informal discussion on biomedical innovations and role of regulatory science.
Fees: The Workshop on June 8-9, 2018 is free and the half-day short course on June 10 is RMB800.
Details and registration['.,: https://www.eventbank.cn/event/15419/
Contact Info: lutian@stanford.edu
Stanford Center at Peking University
5 Yiheyuan Road, Beijing, China
As a recipient of a Stanford Center at Peking University (SCPKU) Team Innovation Faculty Fellowship, Judith Prochaska, an associate professor of medicine, and her colleagues from the Stanford Prevention Research Center, had an opportunity to teach a graduate seminar in Beijing in summer of 2016. In addition to teaching, the fellowship allowed her to connect with in-country scholars and explore new research opportunities. Read more.
Summary
Axonopathy is a typical early characteristic of neurodegenerative diseases in central nervous system (CNS), which leads to axon degeneration and retrograde neuronal cell death. It is critical to decipher the upstream signals that trigger the neurodegeneration cascade to minimize the severe consequences of progressive CNS dysfunction. It is also upmost interest to promote CNS axon regeneration for neural repair. Optic neuropathies are a group of retinal ganglion cell (RGC) diseases with features of axonopathy: they are initiated by optic nerve (ON) injury and that produces secondary RGC death. Prof. Hu’s study of three in vivo mouse models of optic neuropathies (traumatic optic nerve injury, glaucoma and EAE/optic neuritis) revealed that both acute traumatic injury and chronic insult of ON induce endoplasmic reticulum (ER) stress and activate the unfolded protein response (UPR) signal transduction pathways in RGCs. Modulation of two key downstream pathways of ER stress synergistically promote survival of both RGC somata and axons in all three optic neuropathy models, suggest that neuronal ER stress is a general upstream mechanism for both events in CNS axonopathies, and that axon injury-induced ER stress is the link between the sequential events of axon injury and neuronal soma death. Using the same model, we also revealed a complex neuron-intrinsic balancing mechanism involving AKT as the nodal point of PI3K, mTORC1/2 and GSK3β that coordinates both positive and negative cues to regulate adult CNS axon regeneration.
Speaker - Professor Hu Yang
Prof. Hu, Assistant Professor of Ophthalmology at Stanford
University School of Medicine, is also member of Bio-X
and of Stanford Neurosciences Institute. He received the
Doughlas Johnson Award for Glaucoma Research (2013)
and the Knight Templar Eye Foundation Travel Fellowship
Award (2016). Prof. Hu received his Ph.D in Neuroscience
at Weill Medical College of Cornell University and MD from
Beijing Medical University.
Lunch box option provided
Coming to SCPKU
The nearest Peking University entrance to the Center is
the Northeast Gate on Zhongguancun Beidajie. Please
make sure to bring your ID or passport for registration at
the gate. We will send you a reminder and map of the
Center once you have successfully registered. For
inquiries, please call (86) 10 62744170.
Stanford Center at Peking University
Langrun Yuan, Peking University
On July 21, SCPKU was the site of a seminar entitled “Medical Big Data Application Assessment and Safeguards.” Co-sponsored by the Chinese Health Information Association (CHIA) and the China National Health Development Research Center of the People’s Republic of China (NHDRC), this event was the group’s second seminar focused on this topic which gathered over 80 participants including leaders from CHIA, NHDRC, local members of the Health and Family Planning Commission, and academic representatives from universities, medical institutes and pharmaceutical companies. The seminar concentrated on the fusion of medical big data and health care services, decision outcomes, as well as deployment by the State Council and National Health and Family Planning Commission of the People’s Republic of China (NHFPC).
Following NHDRC Director Wei Fu’s opening remarks, Xuefeng Ling, SCPKU Faculty Fellow, Principal Investigator of the Translational Medical Program at Stanford University and co-founder of HBI Solutions, gave a talk on the application of medical big data in decision support. Dr. Ling introduced big data based business intelligent solutions for health management platforms that hold electronic medical records as structured data. Big data based business intelligent solutions have been shown to yield better performance than traditional unstructured solutions in numerous cases including situational awareness, population approach, and risk information.
University of California-Riverside Bioengineering Associate Professor Jiayu Liao followed with a presentation on Chinese medicine and its contribution to medical big data. Dr. Liao cited the latest clinically validated immunosuppressant inspired by Chinese medicine which is cheaper and more effective than its predecessors. He also highlighted the first reported Non-peptide GLP-1R Agonist with in vivo efficacy and a new fluorescence resonance energy transfer technique, both of which are based on Chinese medicine.
Harvard Professor of Statistics and Director of Graduate Studies Jun Liu, West China Hospital Vice President and Professor Wei Zhang, and Taizhou Pharmaceutical High-Tech District Health Bureau Director Tao Zhang separately presented on medical big data applications in medical management and service, medical service evaluation and applications based on diagnosis related groups, and Taizhou’s demand and practices. NHFPC Associate Director and CHIA Chairman Xiaotao Jin and Chinese Academy of Chinese Medical Sciences (CACMS) and Academicians of Chinese Academy of Engineering (CAE) Dean Boli Zhang also presented.
Dr. Ling and Health and Development Center Professor Long Cheng closed the seminar with a discussion focused on early investigations into a medical big data application evaluation index system and an international medical big data human resources development cooperation plan.
Stanford’s Center for Innovative Study Design, with co-sponsors including the Stanford Center at Peking University (SCPKU), the International Society for Biopharmaceutical Statistics and Tsinghua University’s Center for Hospital Management, held a Forum on Regulatory Science and Biomedical Innovations at SCPKU on March 22, 2017. The event gathered more than 60 leaders from the Chinese Food and Drug Administrations (CFDA), Chinese Association of Preventive Medical (CAPM), universities, professional organizations, and R&D experts from domestic and international biopharmaceutical companies.
Over the last decade, significant progress has been made in medical research, disease treatment and general health and well-being. The Chinese government has called out innovation as a major national strategy to achieve sustainable growth. At the same time, to address public health and safety, the country’s regulatory agencies are tasked with implementing relevant laws to ensure the safety and efficacy of new products and services before they’re available to the public. The ability of regulatory agencies, laws and regulations to promote innovation while protecting public health is an important research question. This forum at SCPKU was designed to facilitate a high-level discussion on this topic by scholars from academia from both China and the US, CFDA leaders, and R&D experts from biomedical industries.
The forum was structured with four keynote talks and two panel discussions. Dr. Ruiyi He, the Chief Scientist at the Center for Drug Evaluation of CFDA, delivered a speech on CFDA’s plan to enhance regulations on drug evaluation to promote the development of new drugs. He highlighted some major initiatives to align with ICH (International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use). In June 2017, China became a member of ICH. Dr. Dechao Yu, founder and CEO of the Innovent Biologics, Inc., gave a talk on opportunities and challenges in innovative biologics in China. He shared his experience in developing Oncorine and Conbercept in China and the needs for regulation reform for innovative new drug applications. Professor Jiqian Fang from Sun Yat-Sen University reviewed the development of the CFDA in the past two decades and called for open, transparent and academic participation in innovative development of drug review and approval regulations. Professor Baoyan Liu, Vice President of the Chinese Academy of Chinese Medicine Sciences, presented innovations in Chinese medicine (CM) using clinical trials and big data, and the regulatory needs tailored for the sciences of CM.
The two panel discussions were focused on the challenges and opportunities in evaluating the safety and efficacy of innovative biomedical products and collaboration in biomedical innovations. Panelists included a CFDA division director, CFDA biostatisticians, several members of the CFDA advisory committee, a vice president of CAPM, and CEOs of several biomedical startups in China.
Attendees were able to exchange ideas in an open and fair environment and many expressed interest in joining future SCPKU-based forums and workshops on this topic. Forum participants drew the following conclusions:
· Regulatory science plays an important role in promoting and supporting biomedical innovations.
· Regulatory reforms should be open, transparent, science-driven, and in alignment with international standards.
· Low-quality generic drugs should not be supported.
· Regulatory agencies, academics, and the biopharmaceutical industry should work together on developing science-based policies to make effective, safe and affordable drugs for Chinese patients.
The Center for Innovative Study Design also held a Workshop on Innovative Statistical Methods in Precision Medicine and Big Data at SCPKU on March 23, 2017. Twelve statisticians from the Chinese FDA, Chinese universities and US universities presented their research on advanced clinical trial design, statistical innovations in big data, and applications of machine learning in biomedical data science. More than 60 attendees from local universities (both faculty and graduate students), government, and pharmaceutical companies joined the workshop and had many insightful discussions.
The 2017 Forum will feature a luncheon keynote address on “Primary Care in the Netherlands: Lessons for China” by Jeroen N. Struijs, Senior Researcher in the Department of Quality of Care and Health Economics, National Institute of Public Health and the Environment, The Netherlands. Additional prominent speakers include Dr. Huncheol Bryant Kim, Cornell University, US, speaking on health policy in South Korea; Dr. Bei Lu, University of New South Wales, Australia, speaking on China’s efforts to integrate long-term care with primary care--Experiences of Qingdao’s Long-term Care Insurance program; Dr. Xiaoyun Liu, Peking University, on China’s primary care workforce; Dr. Jiayan Huang, Fudan University, on a model of integrated care from southern China; and Dr. Qiulin Chen, China Academy of Social Sciences, speaking on “Strengthening China’s primary care: A view from Inner Mongolia.” In addition, select policymakers and providers will introduce China's overall healthcare system reforms as well as discuss challenges to strengthening primary care in China.
Stanford Center at Peking University